Olaparib
- TRADE NAME: Lynparza (AstraZeneca)
- INDICATIONS: BRCA-mutated ovarian cancer
- CLASS: Poly (ADP-ribose) polymerase (PARP) inhibitor
- HALF-LIFE: 7–17 hours
FDA APPROVAL DATE: 12/019/2014
CLINICALLY IMPORTANT, POTENTIALLY HAZARDOUS INTERACTIONS WITH:Amprenavir, Aprepitant, Atazanavir, Boceprevir, Bosentan, Carbamazepine, Ciprofloxacin, Clarithromycin, Crizotinib, Darunavir, Diltiazem, Efavirenz, Erythromycin, Etravirine, Fluconazole, Fosamprenavir, Grapefruit Juice, Imatinib, Indinavir, Itraconazole, Ketoconazole, Lopinavir, Modafinil, Nafcillin, Nefazodone, Nelfinavir, Phenytoin, Posaconazole, Rifampin, Ritonavir, Saquinavir, St John's Wort, Strong and moderate CYP3A inhibitors, Telaprevir, Telithromycin, Verapamil, Voriconazole
PREGNANCY CATEGORY: D
Please login to see the rest of this drug profile
Click on the DRUG REVIEW ARTICLE tab (above) to see a review of olaparib in the Taylor & Francis journal Expert Opinion on Drug Safety. (Note that non-subscribers to the journal will only be able to see an abstract of the article.)
Page last updated 10/23/2023
Symbol key
Incidence 
- <1%
- 1-5%
- 5-10%
- 10-15%
- 15-20%
- 20-30%
- >30%
Seriousness
- Hospitalization possible
- Life threatening
- Fatal
Warnings in other populations
- Breast feeding
- Geriatric
- Pediatric
